Innoviva (NASDAQ:INVA – Get Free Report) and Tilray Brands (NASDAQ:TLRY – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Insider & Institutional Ownership
99.1% of Innoviva shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 1.6% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Innoviva and Tilray Brands”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Innoviva | $411.33 million | 3.74 | $271.17 million | $4.10 | 5.19 |
| Tilray Brands | $210.48 million | 2.13 | -$121.40 million | ($1.40) | -2.16 |
Innoviva has higher revenue and earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Innoviva has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Innoviva and Tilray Brands, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Innoviva | 0 | 2 | 4 | 0 | 2.67 |
| Tilray Brands | 2 | 2 | 3 | 1 | 2.38 |
Innoviva presently has a consensus price target of $39.25, suggesting a potential upside of 84.45%. Tilray Brands has a consensus price target of $5.90, suggesting a potential upside of 94.72%. Given Tilray Brands’ higher possible upside, analysts plainly believe Tilray Brands is more favorable than Innoviva.
Profitability
This table compares Innoviva and Tilray Brands’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Innoviva | 81.19% | 28.03% | 20.19% |
| Tilray Brands | -16.91% | -10.39% | -7.38% |
Summary
Innoviva beats Tilray Brands on 12 of the 15 factors compared between the two stocks.
About Innoviva
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
About Tilray Brands
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.
